San Francisco Healthcare Executives Round Table

Please RSVP your interest in attending to Laura@abl.org.

ABL San Francisco Healthcare Executives Round Table

Diagnosing Risk:
New Ways to Predict - and Change - the Future

Round Table Information

Date & Time:
Wed., August 11, 2010
8:00 AM - 11:00 AM

Optional Networking:
Breakfast 7:30 AM
Lunch 11:00 AM
_____________________

Location:
Downtown San Francisco
_____________________

ABL Member &
Strategic Advisory Presenter:
Mike Richey
President
Tethys Bioscience, Inc.
_____________________

2010 Meeting Calendar

Facilitator's Bio:
Mimi Grant

In the wonderful new world of diagnostic innovation, lab tests can identify predispositions to disease or even soft tissue injury. The information these tests reveal can lead providers to recommend - and, most important – patients to make life-style changes or adopt personal training strategies that can dramatically improve their health, longevity, and even enhance their personal performance. Today, several hundred genetic and other tests are currently in use, and more are being developed.

Some of these tests are being marketed Direct-to-Consumer. But taglines like, "There is no stronger antidote for fear than information,” still provoke controversy.

ABL Member, Mike Richey, is the President of Tethys, a cardiometabolic diagnostic company, whose PreDx® Diabetes Risk Score - the company's lead commercial product - is helping physicians to predict and prevent type 2 diabetes. Mike has spent over 20 years in the development and marketing of laboratory tests and biomarkers (blood-borne markers that relate to disease or are associated with susceptibility to disease). When he was at Chiron (now part of Novartis Diagnostics), they developed the tests that are now routinely used to identify HIV and HCV virus levels.

In our Members' Go-Round Discussion, we'll look forward to hearing what types of tests you're seeing and deploying, and how these new diagnostics appear to be working (or not) to help prevent disease or lower the cost of caring for the most expensive segment of healthcare today: the chronically ill.

During Mike's Presentation, he'll give us background on not only Tethys, but this segment of the emerging diagnostic/predictive laboratory field. We'll also look at the company's future plans for identifying/developing new biomarkers; and most important to Mike, he'll want to hear your recommended responses to the next major challenges Tethys is expecting.

Mike Richey
Presidnet
Tethys Bioscience, Inc.

Emeryville, CA
www.tethysbio.com

Mike Richey is President of Tethys Bioscience, a company dedicated to the discovery, development and commercialization of novel biological markers -- biomarkers -- that provide a practical tool to address the growing global challenge of chronic metabolic diseases, such as diabetes.

Founded in 2005, privately held Tethys Bioscience integrates an experienced management team, innovative research based on sound science, a CLIA-certified clinical laboratory, and a commercialization team with extensive experience in diagnostic innovation. Its PreDx Diabetes Risk Score is the company's lead commercial product, which is helping physicians to predict and prevent type 2 diabetes.

Prior to joining Tethys, Mike operated a consulting practice focused on portfolio strategy and value creation for numerous biotech and diagnostic companies. Before that, he worked for Chiron, beginning in 1990, as VP for the Diagnostics Division, with responsibility for worldwide sales, marketing and market development for the company's novel HCV and HIV viral load tests. Many elements of the business model now employed by Tethys were pioneered by Mike during his tenure at Chiron. Earlier, he worked for Abbott Laboratories, initially in Research and Development for the Diagnostics Division and, over the next 12 years, in project management, and sales and marketing management roles. Still earlier, he worked as a clinical microbiologist in a university hospital lab.

Mike earned his BS degree in Laboratory Technology at the University of Oklahoma.

Should you be able to attend, I would like to schedule a 15 - 20 minute phone call between you and this Round Table's Facilitator, Mimi Grant (President of ABL). Mimi would like to share and review with you who our Members are, answer any questions you may have about the ABL and/or the Round Table's format, culture or agenda.

Best wishes,
Laura Grant
Director, Member Services and Events
Adaptive Business Leaders (ABL) Organization

207 E. Memory Lane, Santa Ana, CA 92705
Office: (714) 245-1427 | Fax: (714) 245.1428
Celebrating Over 25 Years of Helping Health and Technology Leaders Grow Great Companies

Follow us on

About the Adaptive Business Leaders (ABL) Organization:
ABL is California’s leading Chief Execu tives’ Organization. ABL provides its Members with executive leadership coaching through its confidential peer CEO Advisory Board Round Tables and executive learning workshops and network of CEO peers and expert resources. ABL supports the needs of its top-level Member Executives (CEOs of publicly traded, private and not-for-profit companies) by providing them a place to draw on the experience, knowledge and skill sets of their peers in a non-competing vertical industry personal advisory board setting. The core component of the ABL CEO Membership experience is the group Round Table meeting. Members meet once a month for a half day with a group of peer CEOs, Presidents, COOs and Division General Managers from non-competing companies all from the same industry (healthcare, technology or Medical Device) in a trusted and confidential board room like setting, which allows the executive Members to tackle topics and enhance their decision making and business performance.